This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eliot L. Berson, MD; Bernard Rosner, PhD; Michael A. Sandberg, PhD; K. C. Hayes, DVM, PhD; Britain W. Nicholson, MD; Carol Weigel-DiFranco; Walter Willett, MD
Boston, Mass

Arch Ophthalmol. 1993;111(11):1463-1465.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We are pleased by the interest generated by our article¹ in the June 1993 issue of the ARCHIVES and welcome the opportunity to reply.

In response to Drs Fielder and Marshall, the ERG is an indicator of visual function in RP for the reasons enumerated in our response to the editorial by Drs Massof and Finkelstein.² Thus, we cannot accept their statement that our publication raises "false hopes." Instead, vitamin A therapy should be accepted for what the data show—a means to slow, in modest degree, the mean rate of decline of remaining retinal function for adults afflicted with RP.

Dr Norton's comments emphasize individual group comparisons while ignoring the factorial design of the study. The factorial study design has been widely used in major clinical trials sponsored by the National Institutes of Health to evaluate two treatment effects in one study with the smallest possible sample . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?